Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00528398 · ClinicalTrials.gov registry record · Phase 2
Idarubicin and High-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia
A Phase 2 study, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 111
- Enrollment target
NCT00528398 is a Phase 2 study that has completed, run by City of Hope Medical Center. The registered enrollment target is 111 participants.
The verdict
NCT00528398, a Phase 2 study, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 111 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as idarubicin and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving idarubicin together with high-dose cytarabine works in treating patients with acute myeloid leukemia.
Interventions
- DRUG cytarabine
- DRUG idarubicin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 1994-09 |
| Est. Completion | 2015-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00528398
The ClinicalTrials.gov registry entry for NCT00528398 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 111 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which cytarabine is the first listed.
NCT00528398 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00528398 about?
NCT00528398 is a clinical study titled "Idarubicin and High-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia". RATIONALE: Drugs used in chemotherapy, such as idarubicin and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. PURPOSE: This phase II...
What is the current status of trial NCT00528398?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 111 participants. The study started on 1994-09. Estimated completion is 2015-12.
What interventions are being tested in trial NCT00528398?
The interventions under investigation include: cytarabine (DRUG), idarubicin (DRUG).
Who is sponsoring clinical trial NCT00528398?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.